IL4I1 and cancer: However, identification of novel targets such as IL4I1, exploration of alternative strategies such as targeting of downstream pathways (e.g., the AhR pathway) and rational selection of combination therapies should additionally receive adequate focus, as these may well serve to overcome the current limitations of cancer immunotherapies.